CRISPR Stock Market Sentiment

CRSP
 Stock
  

USD 60.77  2.23  3.54%   

CRISPR investor sentiment overview provides quick insight into current market opportunities from investing in CRISPR Therapeutics AG. The current market sentiment together CRISPR Therapeutics' historical and current headlines can help investors to time the market. Many technical investors use CRISPR Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Continue to CRISPR Therapeutics Hype Analysis, CRISPR Therapeutics Correlation and CRISPR Therapeutics Performance.
  
Refresh
CRISPR Therapeutics stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of CRISPR daily returns and investor perception about the current pice of CRISPR Therapeutics AG as well as its diversification or hedging effects on your existing portfolios.

CRISPR Therapeutics Current Investor Sentiment

Investor biases related to CRISPR Therapeutics' public news can be used to forecast risks associated with investment in CRISPR. The trend in average sentiment can be used to explain how an investor holding CRISPR can time the market purely based on public headlines and social activities around CRISPR Therapeutics AG. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
CRISPR Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for CRISPR Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average CRISPR Therapeutics' news discussions. The higher the estimate score, the more favorable is the investor's outlook on CRISPR Therapeutics.
six days ago at www.investorsobserver.com         
Where Will Crispr Therapeutics AG Stock Go Next After It Is Higher By 1.31 percent in a Week - Inves...
Investors Business Daily at Macroaxis
over a week ago at www.benzinga.com         
Statistics on Global CRISPR Genome Editing Market Size Share to Surpass USD 15.84 Billion by 2028, E...
benzinga news
over a week ago at www.nasdaq.com         
CRISPR Therapeutics AG Moves 8.3 percent Higher Will This Strength Last - Nasdaq
nasdaq News
over two weeks ago at www.marketscreener.com         
Transcript CRISPR Therapeutics AG Presents at Goldman Sachs 43rd Annual Global Healthcare Conference...
news
over two weeks ago at www.marketscreener.com         
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With ...
news
over two weeks ago at www.macroaxis.com         
Acquisition by Fleming Harold Edward of 12000 shares of CRISPR Therapeutics subject to Rule 16b-3
Macroaxis News
over two weeks ago at simplywall.st         
After losing 38 percent in the past year, CRISPR Therapeutics AG institutional owners must be reliev...
Simply Wall St News at Macroaxis
over three weeks ago at www.marketscreener.com         
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001 at the 2022 ...
news
over three weeks ago at www.benzinga.com         
CRISPR Therapeutics to Host Innovation Day on June 21, 2022 - Benzinga - Benzinga
benzinga news
over a month ago at www.macroaxis.com         
Acquisition by Morrow Phuong Khanh of 90000 shares of CRISPR Therapeutics subject to Rule 16b-3
Macroaxis News
over a month ago at www.nasdaq.com         
CRISPR Therapeutics AG Shares Close the Week 21.4 percent Higher - Weekly Wrap - Nasdaq
nasdaq News
over a month ago at www.prnewswire.com         
Why Orphan Drug Designation Offers Several Benefits - PR Newswire
prnewswire News
over a month ago at www.streetinsider.com         
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, MD, FACP, as Chief Medical Off...
Street Insider News
over a month ago at finance.yahoo.com         
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T T...
Yahoo News
over a month ago at www.marketbeat.com         
CRISPR Therapeutics Sets New 52-Week Low Following Analyst Downgrade - MarketBeat
Marketbeat News
There is far too much social signal, news, headlines, and media speculation about CRISPR Therapeutics that is available to investors today. That information is available publicly through CRISPR media outlets and privately through word of mouth or via CRISPR internal channels. However, regardless of the origin, that massive amount of CRISPR data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CRISPR Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CRISPR Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CRISPR Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CRISPR Therapeutics alpha.

CRISPR Therapeutics Performance against DOW

 Price Growth (%)  
      Timeline 
1
CRISPR Therapeutics AGs Stocks On An Uptrend Are Strong Fina...04/05/2022
2
Is Now the Time to Bet on This Game-Changing Stock - Nasdaq04/14/2022
3
CRISPR to Report Q1 Earnings Whats in the Cards - Yahoo Fina...04/22/2022
4
CRISPR Therapeutics Provides Business Update and Reports Fir...05/09/2022
5
CRISPR Therapeutics Announces Oral Presentation of New Clini...05/12/2022
6
Financial Statements05/16/2022
7
CRISPR Therapeutics AG Shares Close the Week 21.4 percent Hi...05/19/2022
8
Acquisition by Morrow Phuong Khanh of 90000 shares of CRISPR...05/24/2022
9
Vertex and CRISPR Therapeutics Announce Acceptance of Late-B...06/02/2022
10
Acquisition by Fleming Harold Edward of 12000 shares of CRIS...06/10/2022
11
Unclassified Event06/13/2022
12
Financial Statements06/21/2022
13
Statistics on Global CRISPR Genome Editing Market Size Share...06/22/2022
Continue to CRISPR Therapeutics Hype Analysis, CRISPR Therapeutics Correlation and CRISPR Therapeutics Performance. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.